Semaglutide Improves Kidney Disease and Diabetes Outcomes
The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide helps prevent the progression of chronic kidney disease in patients with type 2 diabetes, indicate data published in The New England Journal of Medicine (2024 May 24. doi:10.1056/NEJMoa2403347). The results were so promising that Novo Nordisk, which funded the research, ended the study early.
“Semaglutide will be another game changer (in addition to sodium-glucose